Available Technologies

INTRODUCTION

Protein aggregation that leads to plaque formation is a contributor in many degenerative diseases including Alzheimer’s, Parkinson’s, Type 2 diabetes, and other amyloidosis diseases. Once these plaques are formed, they are extremely difficult to degrade. Breakdown and even inhibition of oligomers before formation of these plaques is an important step in pre-disease treatments. A therapeutic is needed that can target the specific proteins involved in aggregation for each of these diseases and inhibit oligomer formation, slowing the progression of the disease and making life more comfortable and fulfilling for the patient. Furthermore, drugs that can act on plaque formations and degrade them alongside oligomer inhibition would be a powerful tool to stop the progression of degenerative diseases.

DESCRIPTION OF TECHNOLOGY

This technology uses small molecules to inhibit oligomer formation and even breakdown mature fibrils of plaques. The compounds bind to the protein involved in aggregation and stabilizes it in its monomeric form to inhibit aggregation. This technology involves several groups of compounds that are shown to be specific for single degenerative disease and also have broad spectrum inhibitory activity against multiple diseases such as Alzheimer’s and Type 2 diabetes disease. In addition, these compounds work with other pre-disease measures to slow the progression of degenerative diseases.

BENEFITS

• Inhibits oligomers: Compound inhibits oligomer formation which would form the plaque
• Degrades plaque: Compound degrades mature fibrils of already formed plaque
• Slows progression of disease: Can be used as a pre-disease drug to slow/stop progression
• Specific and general targets:

• Compounds that are specific for one protein associated with a degenerative disease
• Compounds that act on multiple degenerative disease targets

APPLICATIONS

• Human Degenerative Diseases:

• Type 2 diabetes
• Alzheimer’s disease
• Parkinson’s disease
• Huntington’s disease
• ALS disease
• Transthyretin amyloidosis

• Animal Degenerative Diseases:

• Type 2 diabetes
• Prion diseases

PATENT STATUS

None